|
|
???tair.name??? >
???browser.page.title.title???
|
Showing items 551391-551415 of 2348487 (93940 Page(s) Totally)
<< < 22051 22052 22053 22054 22055 22056 22057 22058 22059 22060 > >>
View [10|25|50] records per page
| 國立臺灣大學 |
2008 |
Lipoprotein(a) and Cardiovascular Disease in Ethnic Chinese: The Chin-Shan Community Cardiovascular Cohort Study
|
Chien, Kuo-Liong; Hsu, Hsiu-Ching; Su, Ta-Chen; Sung, Fung-Chang; Chen, Ming-Fong; Lee, Yuan-Teh |
| 臺大學術典藏 |
2018-09-10T07:10:09Z |
Lipoprotein(a) and cardiovascular disease in ethnic Chinese: The Chin-Shan community cardiovascular cohort study
|
Chien, Kuo-Liong; Hsu, Hsiu-Ching; Su, Ta-Chen; Sung, Fung-Chang; Chen, Ming-Fong; Lee, Yuan-Teh; Chien, Kuo-Liong; TA-CHEN SU; Hsu, Hsiu-Ching; KUO-LIONG CHIEN; Su, Ta-Chen; Sung, Fung-Chang; Chen, Ming-Fong; Lee, Yuan-Teh |
| 亞洲大學 |
1990-07 |
Lipoprotein(a) enhances plasma clot lysis in vitro
|
Mao SJT; Tucci MA |
| 國家衛生研究院 |
2004-02 |
Lipoprotein(a) is an independent risk factor for peripheral arterial disease in chinese type 2 diabetic patients in Taiwan
|
Tseng, CH |
| 國立臺灣大學 |
2004 |
Lipoprotein(a) Is an Independent Risk Factor for Peripheral Arterial Disease in Chinese Type 2 Diabetic Patients in Taiwan
|
曾慶孝; TSENG, CHIN-HSIAO |
| 臺大學術典藏 |
2018-09-10T04:46:54Z |
Lipoprotein(a) Is an Independent Risk Factor for Peripheral Arterial Disease in Chinese Type 2 Diabetic Patients in Taiwan
|
Tseng, C.-H.; CHIN-HSIAO TSENG |
| 臺大學術典藏 |
2020-06-01T08:34:02Z |
Lipoprotein(a) Is an Independent Risk Factor for Peripheral Arterial Disease in Chinese Type 2 Diabetic Patients in Taiwan
|
Chin-Hsiao Tseng; CHIN-HSIAO TSENG |
| 亞洲大學 |
1983 |
Lipoprotein, lyzosomes, and biliary lipids
|
LaRusso NF;Kawamoto T;Mao SJT;Sewell RB. |
| 東海大學 |
2011 |
Lipoprotein-associated phospholipase A 2 interacts with phospholipid vesicles via a surface-disposed hydrophobic α-helix
|
Cao, J.a, Hsu, Y.-H.a, Li, S.b, Woods, V.L.b, Dennis, E.A. |
| 國立臺灣大學 |
2004 |
Lipoprotein-X Reduces Ldl Atherogenicity in Primary Biliary Cirrhosis by Preventing Ldl Oxidation
|
張博淵; 呂紹俊; 蘇大成; 周三芳; 廖朝崧; 李源德; CHANG, PO-YUAN; LU, SHAO-CHUN; SU, TA-CHEN; CHOU, SAN-FANG; LIAU, CHIAU-SUONG; LEE, YUAN-THE |
| 中國醫藥大學 |
2004 |
Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation
|
(Po-Yuan Chang); (Shao-Chun Lu); (Ta-Chen Su); (San-Fang Chou); (Wen-Huei Huang); (Joel D. Morrisett); 陳珠璜(Chu-Huang Chen); (Chiau-Suong Liau); 李源德(Yuan-Teh, Lee) |
| 臺大學術典藏 |
2018-09-10T04:49:21Z |
Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation
|
Chang, P.-Y. and Lu, S.-C. and Su, T.-C. and Chou, S.-F. and Huang, W.-H. and Morrisett, J.D. and Chen, C.-H. and Liau, C.-S. and Lee, Y.-T.; TA-CHEN SU |
| 臺大學術典藏 |
2020-02-06T08:11:33Z |
Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation
|
Chang P.-Y.; SHAO-CHUN LU; Su T.-C.; Chou S.-F.; Huang W.-H.; Morrisett J.D.; Chen C.-H.; Liau C.-S.; Lee Y.-T.; Chang P.-Y.;Shao-Chun Lu;Su T.-C.;Chou S.-F.;Huang W.-H.;Morrisett J.D.;Chen C.-H.;Liau C.-S.;Lee Y.-T. |
| 臺大學術典藏 |
2020-09-28T02:48:05Z |
Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation
|
Chang P.-Y.;Lu S.-C.;Ta-Chen Su;Chou S.-F.;Huang W.-H.;Morrisett J.D.;Chen C.-H.;Liau C.-S.;Lee Y.-T.; Chang P.-Y.; Lu S.-C.; TA-CHEN SU; Chou S.-F.; Huang W.-H.; Morrisett J.D.; Chen C.-H.; Liau C.-S.; Lee Y.-T. |
| 臺大學術典藏 |
2004 |
Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation
|
Morrisett J.D.; Huang W.-H.; Chou S.-F.; Su T.-C.; Lu S.-C.; PO-YUAN CHANG; Chen C.-H.; Liau C.-S.; Lee Y.-T. |
| 高雄醫學大學 |
2004 |
Liposomal doxorubicin 治療引起的肢端紅斑症
|
薛強文;沈育如;陳國熏 |
| 義守大學 |
2017-04 |
Liposomal Encapsulation for Systemic Delivery of Propranolol via Transdermal Iontophoresis Improves Bone Microarchitecture in Ovariectomized Rats
|
Benjamin Teong;Shyh Ming Kuo;Wei-Hsin Tsai;Mei-Ling Ho;Chung-Hwan Chen;Han Hsiang Huang |
| 國家衛生研究院 |
2018-11 |
Liposomal irinotecan (nal-IRI) plus 5-FU/LV in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) progressing on gemcitabine-based treatment: Further subgroup analyses of the pivotal NAPOLI-1 study
|
Chen, LT;Mercade, TM;Lee, KH;Lakatos, G;Wang-Gillam, A;Mirakhur, B;de Jong, F |
| 國家衛生研究院 |
2020-01 |
Liposomal irinotecan + 5-FU/LV in metastatic pancreatic cancer: Subgroup analyses of patient, tumor, and previous treatment characteristics in the pivotal NAPOLI-1 trial
|
Macarulla Mercade, T;Chen, LT;Li, CP;Siveke, JT;Cunningham, D;Bodoky, G;Blanc, JF;Lee, KH;Dean, A;Belanger, B;Wang-Gillam, A |
| 國立成功大學 |
2020 |
Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial
|
MacArulla, Mercad� T.;Chen, L.-T.;Li, C.-P.;Siveke, J.T.;Cunningham, D.;Bodoky, G.;Blanc, J.-F.;Lee, K.-H.;Dean, A.;Belanger, Belanger B.;Wang-Gillam, A. |
| 國家衛生研究院 |
2019-03-04 |
Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial
|
Macarulla, T;Blanc, JF;Wang-Gillam, A;Chen, LT;Siveke, JT;Mirakhur, B;Chen, J;de Jong, FA |
| 國立成功大學 |
2019 |
Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer – A subgroup analysis of the pivotal NAPOLI-1 trial
|
Macarulla, T.;Blanc, J.-F.;Wang-Gillam, A.;Chen, L.-T.;Siveke, J.T.;Mirakhur, B.;Chen, J.;de, Jong F.A. |
| 國家衛生研究院 |
2019-12-01 |
Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study
|
Bang, YJ;Li, CP;Lee, KH;Chiu, CF;Park, JO;Shan, YS;Kim, JS;Chen, JS;Shim, HJ;Rau, KM;Choi, HJ;Oh, DY;Belanger, B;Chen, LT |
| 國立成功大學 |
2020 |
Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study
|
Bang, Y.-J.;Li, C.-P.;Lee, K.-H.;Chiu, Chiu C.-F.;Park, J.O.;Shan, Y.-S.;Kim, J.S.;Chen, J.-S.;Shim, H.-J.;Rau, K.-M.;Choi, H.J.;Oh, D.-Y.;Belanger, Belanger B.;Chen, L.-T. |
| 中山醫學大學 |
2021 |
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study
|
Chiu, TJ; Su, YY; Yang, SH; Li, CP; Bai, LY; Chiang, NJ; Chuang, SC; Shan, YS; Chan, DC; Chen, LT; Yen, CJ; Peng, CM; Chen, YY; Chen, JS; Chou, WC |
Showing items 551391-551415 of 2348487 (93940 Page(s) Totally)
<< < 22051 22052 22053 22054 22055 22056 22057 22058 22059 22060 > >>
View [10|25|50] records per page
|
